Notice of NIDA's Participation in PAR-21-277, " Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)"
Notice Number:
NOT-DA-22-057

Key Dates

Release Date:

April 12, 2022

Related Announcements

PAR-21-277 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating in PAR-21-277, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)", effective immediately.

The following sections of PAR-21-277 have been modified to reflect NIDA's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

Assistance Listing Number(s)

93.279

Part 2. Full Text of Announcement

Program Considerations

NIDA: NIDA will support applications related to addiction sciences, including, but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, development of new and improved strategies to prevent substance use and its consequences, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, HIV and drugs of abuse (including basic discovery science research as well as applied research on delivery of HIV and substance use prevention and treatment services to persons who use drugs), medication development, epidemiology, identifying the biological, environmental, behavioral, and social causes and consequences of substance use and addiction across the lifespan, and implementation science, including secondary data analysis. In all these and related areas of addiction sciences research, NIDA encourages an emphasis on understanding and addressing health disparities which are experienced by vulnerable populations. The NIDA seeks applications that will address questions relevant to the NIDA mission, supports research across NIDA's portfolio, and aligns with the NIDA's Strategic Vision. Please refer to the NIDA website for more details on the research priorities of the NIDA.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Albert Avila, Ph.D.
Director, Office of Diversity and Health Disparities
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: aavila@nida.nih.gov

Financial/Grants Management Contact(s)

Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301- 480-1159
Email: pfleming@nida.nih.gov

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Albert Avila, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: aavila@nida.nih.gov